Eli Lilly (LLY) shares snapped six straight days of losses as the stock closed 1.39% higher, at $812.76 on Friday. The ...

Eli Lilly (NYSE:LLY) recently announced several significant events, including promising trial results for baricitinib in ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

People without diabetes can lose up to 13% of their starting weight in 6 months using tirzepatide (Mounjaro) as an off-label ...

In the ever-evolving landscape of healthcare, groundbreaking innovations are not merely celebrated for their scientific ...

Novo Nordisk is a great pick to buy with the stock near its 52-week low. Vertex Pharmaceuticals is helping patients and ...

Eli Lilly’s rising fortunes tied to its weight loss and diabetes drugs led to a nine-figure payday for its top executive.

Proficio Capital Partners LLC lifted its holdings in Eli Lilly and Company (NYSE:LLY – Free Report) by 30.2% in the fourth ...

A rise in the use of non-FDA-approved diabetes and obesity medications has spurred health care professionals and medical ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Shares of Eli Lilly and Company (NYSE:LLY – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the ...